The human N-terminal acetyltransferases (NATs) catalyze the transfer of acetyl moieties to the N-termini of 80 --90% of all human proteins. Six NAT types are present in humans, NatA --NatF, each is composed of specific subunits and each acetylates a set of substrates defined by the N-terminal amino-acid sequence. NATs have been suggested to act as oncoproteins as well as tumor suppressors in human cancers, and NAT expression may be both elevated and decreased in cancer versus non-cancer tissues. Manipulation of NATs in cancer cells induced cell-cycle arrest, apoptosis or autophagy, implying that these enzymes target a variety of pathways. Of particular interest is hNaa10p (human ARD1), the catalytic subunit of the NatA complex, which was coupled to a number of signaling molecules including hypoxia inducible factor-1a, b-catenin/cyclin D1, TSC2/mammalian target of rapamycin, myosin light chain kinase , DNA methyltransferase1/E-cadherin and p21-activated kinase-interacting exchange factors (PIX)/Cdc42/Rac1. The variety of mechanistic links where hNaa10p acts as a NAT, a lysine acetyltransferase or displaying a non-catalytic role, provide insights to how hNaa10p may act as both a tumor suppressor and oncoprotein.
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The amino-acid sequences of the N-termini determine which proteins are Nt-acetylated and by which NAT the acetylation is catalyzed. 2, 25, 26 In humans, six different NATs have been defined on the background of their unique subunits and their defined set of substrates, although in recent years it was discovered that there exists some overlap in the substrate profiles of the different NATs. The human NATs have been classified as hNatA, hNatB, hNatC, hNatD, hNatE and hNatF, where all have been found to associate with ribosomes. Figure 1 summarizes the current knowledge about their subunit composition and substrate specificities. 1,2,15,27 --33 The NatA-E complexes are conserved throughout evolution from yeast to humans with respect to substrate specificity and the composition of the complexes. 25,34 --36 NatF, on the other hand, is present only in higher eukaryotes and its presence may partially explain the higher level of Nt-acetylation seen in humans as compared with yeast. 2 Some of the catalytic NAT subunits were also demonstrated to catalyze N-e-acetylation, which is the acetylation of e-lysine groups on internal sites of proteins. This reaction is normally catalyzed by lysine acetyltransferases (KATs). 37 The fact that NAT subunits are also found in non-ribosomal forms, including in the nucleus, 15,28 --30 may suggest that they have functions besides the cotranslational Nt-acetyltransferase activity.
Very recently, a mutation in hNAA10 was shown to be the underlying cause of Ogden syndrome, a lethal infantile syndrome in males. The resulting hNaa10p-Ser37Pro protein displayed reduced NAT-activity, in agreement with a functional hNaa10p being essential for development and life in humans. 38 This is so far the only NAT-mutation directly linked to disease.
The hallmarks of cancerous cells are their ability to escape apoptosis, sustain an active cell proliferation and eventually invade other tissues. Induction of apoptosis and/or reducing the cell proliferation in cancer cells could retard the cancerous tissue from developing and cure the patient. In the search for ways to combat cancer, NATs and especially hNaa10p have emerged as potential candidates for this task. In this review we will summarize the current knowledge of the NATs in relation to cancer and provide an overview of the properties of hNaa10p supporting its candidacies as an oncoprotein and tumor suppressor.
Naa10p AS A PRO-PROLIFERATIVE AND ANTI-APOPTOTIC PROTEIN IN CANCER CELLS
During the last couple of years, several studies have shed light on the biological importance of hNaa10p and the human NatA complex in cancer cells, both with respect to expression patterns and the multiple cellular pathways under its control. A growing number of studies have reported that a high expression of hNaa10p in certain cancers seems to correlate to a low survival rate and aggressiveness of tumors. 39, 40 NAA10 was found overexpressed in cancers of different types and tissues such as hepatocellular carcinoma, 41 colorectal cancer, 40, 42 lung cancer 39, 42 and breast cancer. 42, 43 Overexpression of hNaa10p was also reported in the urinary bladder cancer, breast cancer and cervical carcinoma. 42 Experiments with the MCF-7 breast cancer cell line show that expression of hNaa10p increases the proliferation of this cell line by promoting passage of the G1/S and G2/M checkpoints as suggested by flow cytometry analysis. 43 The same study also confirmed that hNaa10p expression is significantly higher in the breast cancer tissue than in tissue adjacent to the cancerous tissue. 43 Indeed, ectopic expression of hNaa10p increased cell proliferation and upregulation of genes involved in cell survival, proliferation and metabolism. 44 Among them was Beclin 1, a protein involved in autophagy and anti-apoptotic pathways. 45 In agreement with these findings, it was observed that the cell proliferation was markedly reduced in hNAA10 knockdown cells. These studies strongly support a role for hNaa10p in promoting cell proliferation and cell survival.
Furthermore, early studies reported that siRNA mediated knockdown of hNAA10 and hNAA15 resulted in a significant reduction of viable HeLa cells. This reduction in viability was apparently caused by caspase-dependent apoptosis of G0/G1 phase cells. 46 This phenotype was recently also confirmed for human colon carcinoma HCT116 p53 þ / þ cells treated with sihNAA10, whereas HCT116 p53 À / À cells showed reduced cell growth. 47 This latter study also pointed to pathways implicated in the sihNAA10-induced apoptosis. Depletion of hNaa10p leads to activation and stabilization of p53, specifically by phosphorylation of Ser 15 . This indicates that the apoptosis observed is p53 dependent, and depletion of hNaa10p indeed leads to increased transcription of p53-dependent pro-apotopic genes. The same study shed light on the events upstream of p53 activation. They reported that gH2A.X and chk2 were activated by phosphorylation independent of the functional status of TP53. As activation of gH2A.X and chk2 is normally seen with double-strand DNA breaks, Gromyko et al. 47 postulated that depletion of hNaa10p and consequently loss of hNatA activity result in DNA damage signaling through gH2A.X/chk2 module and phosphorylation of Ser 15 of p53 leading to the ultimate fate of apoptosis. Three anaplastic thyroid carcinoma cell lines with non-functional TP53 were in the same study reported to be sensitized to chemotherapeutic drugs in a drug and cell type specific manner by hNAA10 knockdown. 47 In non-small lung cell cancer cells, knockdown of hNAA10 was shown to suppress cell proliferation due to reduced cyclin D1 expression. 48 This tendency was also reported in two anaplastic thyroid carcinoma cell lines with non-functional TP53. 47 In addition, the latter study also reported reduced levels of cyclin E and an upregulation of cyclin-dependent kinase inhibitor p27/Kip1, possibly contributing to cell-cycle arrest. 47 Apparently, the observed effects in non-small lung cell cancer cells are mediated via hNaa10p catalyzed N-e-acetylation of one or more lysine residues of b-catenin, a known regulator of cyclin D1 through binding to the cyclin D1 promoter. 48 In addition, hNaa10p synergetically activates the cyclin D1 promoter by activating AP-1 proteins (c-Jun and c-Fos) via the ERK1/2 pathway and in complex with b-catenin induce the transcription of the cyclin D1 promoter. 49 Cyclin D1 is a prominent regulator of cell proliferation and has been coupled to tumorigenesis. 50, 51 In a separate study where hNaa10p was depleted from anaplastic thyroid carcinoma cells by RNAi, it was reported that the acetylation status of b-catenin was unchanged. 47 This could indicate that growth inhibition and cell-cycle arrest mediated by reduced levels of cyclin D1 can be independent of the hNaa10p-mediated regulation of b-catenin, perhaps solely mediated via the ERK1/2-AP-1 pathway.
Studies by Lee et al. 39 suggest yet another interaction partner of hNaa10p that may influence its oncogenic properties, DNA methyltransferase1 (DNMT1). DNMT1 is responsible for the methylation of DNA and aberrant methylation is characteristic of tumor development. 52, 53 hNaa10p directly interacts with DNMT1 and increases its enzymatic capability in an acetyltransferase (AT)-independent manner by facilitating the interaction between DNMT1 and its substrate DNA. Specifically, the oncogenic potential of hNaa10p lies within its capability to recruit DNMT1 to the E-cadherin promoter, where DNMT1 can silence the Figure 1 . Overview of human NATs and their substrate specificities. The human NATs are composed of catalytic subunits (yellow) and auxiliary subunits (green), and all are associated with ribosomes (blue). NatA potentially acetylates Ser-, Ala-, Thr-, Gly-and Val-N-termini after the iMet has been removed by methionine aminopeptidases (MetAPs). NatB potentially acetylates Met-Asp-, Met-Glu-and Met-Asn-, whereas NatC may target Met-Leu-, Met-Ile-, Met-Phe-and Met-Trp-. NatD apparently only acetylates the Ser-N-termini of histones H2A and H4. NatE and NatF demonstrate some specificity towards NatC-type substrates as well as Met-Lys-, Met-Ala-, Met-Met-and Met-Val-. *NatA or hNaa10p may also mediate post-translational acetylation of mature actins harboring Asp-and Glu-N-termini.
transcription of the tumor suppressor E-cadherin through methylation.
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Naa10p AS AN ANTI-PROLIFERATIVE AND PRO-APOPTOTIC PROTEIN IN CANCER CELLS
The role of hNaa10p and hNatA in cell proliferation and evasion of apoptosis makes it tempting to brand it as an oncoprotein that could in part be responsible for tumorigenesis and tumor growth. However, there are several studies reporting that a highexpression pattern of hNaa10p is not detrimental for the patient or that some tumors exhibit a reduced level of expressed hNaa10p. In fact, many of these studies indicate that hNaa10p has tumor suppressor properties.
The high level of hNaa10p expression in certain cancers seems to correlate to a low survival rate and aggressiveness of tumors, but recent reports show that a high-expression pattern of hNaa10p does not necessarily correlate with a poor prognosis. Kuo et al. 54 report that high expression of hNaa10p in breast cancer correlate to small tumors, few lymph node metastases and better prognosis, whereas a low expression level of hNaa10p is associated with a poor prognosis, large tumors and more lymph node metastases. In line with this, a study by Hua et al. 55 points out that hNaa10p expression remains high in early, primary tumors but is reduced significantly in tumors with lymph node metastasis. Indeed, xenograft experiments by this group indicate that ectopic hNaa10p expression suppress tumor growth and metastasis. Hua et al. suggest that the downregulation of hNaa10p is a critical step in tumor progression and suggests a mechanistic explanation to this phenomenon. The ability of hNaa10p to reduce cancer cell motility was apparently linked to its binding partners p21-activated kinase-interacting exchange factors (PIX), proteins involved in the regulation of cell migration in complex with G protein coupled receptor kinase-interacting proteins and paxillin. When hNaa10p binds PIX, it disrupts the binding between PIX and G protein coupled receptor kinase-interacting. This prevents the localization of PIX to the plasma membrane and subsequently inhibits the activation of Rac1/Cdc42 and cell migration. This activity is apparently independent of its binding partner hNaa15p and the AT activity of the protein. 55 Shin et al. 56 also report that reduced levels of hNaa10p promote cell migration although by a different pathway. They demonstrate that hNaa10p inhibit cell motility by inactivating myosin light chain (MLC) kinase by direct binding and N-e-acetylation. Inactivation of MLC kinase results in reduced levels of phosphorylated MLC, which in turn leads to reduced cell motility. The MLC kinase -MLC pathway is part of the machinery responsible for cell contraction and migration. Reduced levels of hNaa10p significantly increased the motility of the cancer cell lines used (HEK293 and HT1080), whereas overexpression suppressed the migration of these cells.
The different pathways are not necessarily mutually exclusive and may very well be present at the same time in the cell. However, more experimental results are necessary to confirm if the regulation of hNaa10p expression is required for tumor progression, where hNaa10p potentially contributes to increased proliferation in growing tumors and gets downregulated as the tumor progresses in its development towards metastasis.
The tumor suppressor properties of hNaa10p do not seem to be exclusively linked to its ability to affect cell motility, but also appears to play a role in autophagy, a process that degrade proteins and organelles for the reuse of their components. Autophagy is therefore believed to be closely related to the survival strategies of the cell. Contradictory to this cell survival function, autophagy can induce a type of programmed cell death, called cell death type II or autophagic cell death, that is different from apoptosis, 57 Kuo et al. 54 reported that breast cancer cell lines that stably overexpressed hNaa10p exhibited reduced cell growth and tumorigenicity. This property of hNaa10p was attributed by stabilization of TSC2 through direct interaction and Nt-acetylation. Stabilization and thus increased abundance of TSC2 was thought to suppress the mammalian target of rapamycin signaling pathway and thereby promote autophagy and possibly reducing cell proliferation as a consequence.
Yi et al. 58 have demonstrated that depletion of hNaa10p have no effect on cell-cycle progression. The same group also reported that hNaa10p may promote cell death as hNaa10p depletion imparts resistance to apoptosis in cells with induced DNA damage, probably through suppression of caspase 2, 3 and 9 activities. 58, 59 hNaa10p seems to be a truly diverse protein with the capability of inducing its effects not only through its major activity as a NAT, but also through N-e-acetylation, directly and/or by recruiting interaction partners with KAT activity. In addition, hNaa10p is able to directly interact with other proteins to enhance their intrinsic activities or inhibit the activity of its binding partner in an AT-independent manner. These mechanistic features of how hNaa10p can regulate the life and death of cancer cells are outlined in Figure 2 .
THE REGULATION OF hNaa10P IN RESPONSE TO METABOLISM AND HYPOXIA
A well-known characteristic of cancer cells is their heightened level of metabolism, often coupled with increased uptake of glucose and the ability to drive glycolysis even in oxygen-rich environments (the Warburg's effect). 60 It has been proposed that cancer cells use the bulk of the glucose uptake to generate precursor molecules such as NADPH and Ac-CoA to be used in macromolecule synthesis, an important event for actively proliferating cells. 61 Interestingly, it was recently found that the activity of hNaa10p can be regulated in the response to the level of the metabolite AcCoA, suggesting that hNaa10p mediated Nt-acetylation depends on the metabolic state of the cell. 59 Specifically, Yi et al. demonstrated that reduced levels of Ac-CoA by inhibition of Ac-CoA production through the activity of the anti-apoptotic factor Bcl-xL leads to reduced levels of Nt-acetylation of essential apoptotic mediators. Thus, the Bcl-xL-mediated regulation of Ac-CoA regulates apoptosis via Nt-acetylation. The same study also showed that reduced levels of Ac-CoA mediated by Bcl-xL do not affect e-acetylation of histones H3 and H4. 59 This suggests that the level of Ac-CoA can regulate acetylation in an AT-specific manner.
A condition tightly linked to cellular metabolism is hypoxia. In large solid tumors, hypoxia activates the hypoxia inducible factor-1 (HIF-1) transcriptional complex which has a major role in promoting tumor survival under these conditions. 62 --65 HIF-1a is the oxygen regulated component of HIF-1 and is stabilized and activated during hypoxia. 66 --69 This is regarded as a turning point for tumors as HIF-1 can induce angiogenesis, cell migration or resistance to chemotherapy. 70 The activity of b-catenin is inhibited during hypoxic conditions by HIF-1a. HIF-1a inhibits acetylation of b-catenin by binding directly to hNaa10p in a competitive manner. 71 This prevents the transcriptional activity of b-catenin in cells with Wnt signaling pathways, and thereby inhibits cellular proliferation. Thus in human cancer cells, HIF-1a is a regulator of hNaa10p, while there is currently no strong evidence for hNaa10p being a regulator of HIF-1a, which was suggested in early studies. 44,72 --74 Whether hypoxic conditions and induction of HIF-1a may influence NatA-mediated Nt-acetylation remains to be investigated.
THE ROLE AND EXPRESSION OF OTHER NatA SUBUNITS IN CANCER CELLS
hNaa15p, the auxiliary subunit of the hNatA complex has also been linked to cancer. NAA15 (called NATH in this study) Protein N-terminal acetyltransferases in cancer TV Kalvik and T Arnesen was expressed at high levels in papillary thyroid carcinomas when compared with non-neoplastic thyroid tissue at both mRNA and protein levels. 75, 76 NAA15 expression was particularly high in poorly or undifferentiated components. Interestingly, hNaa15p (called Tubedown in this study) was found to be overexpressed in neuroblastomas associated with a poor prognosis. 77 This protein is highly expressed in advanced stage tumors whereas it is expressed at lower levels in more differentiated subsets of neuroblastomas. The more differentiated ganglioneuroblastoma tumors with low levels of NAA15 are associated with a better histopathology, suggesting that hNaa15p may have a role in the differentiation status and aggressiveness of neuroblastomas and possibly other tumors.
Earlier studies demonstrated that NAA15 was downregulated during differentiation of embryonal endothelial cells, pro-myeloid and myeloid leukemia cells. 78, 79 Also, NAA10 appears to be coregulated with NAA15 during differentiation. 79, 80 Furthermore, NAA15 (called Ga19 in this study) was found to be overexpressed in gastric cancer. 81 hNaa11p, a human paralogue of hNaa10p with similar properties, 79 was found to be associated with loss of heterozygosity in hepatocellular carcinomas. This inactivation of the NAA11 allele was shown to correlate to a low survival rate. 82 A complete overview of the current knowledge of the expression patterns of hNaa10p, hNaa11p and hNaa15p is given in Table 1 .
THE ROLE AND EXPRESSION OF OTHER NATs IN CANCER CELLS
Although the bulk of studies have focused on the hNatA complex and its subunits and how it affects the life and death of cancer cells, a few studies have investigated the role of the other NATs in cancer cells.
Knockdown studies of the hNatB complex in cancer cell lines showed that hNatB has a role in cell proliferation and cell-cycle progression. Depletion of the catalytic subunit hNaa20p sensitized cells to pro-apoptotic stimuli 83 and decreased the G 0 /G 1 fraction Figure 2 . Overview of how the NAT, KAT and AT-independent functions of hNaa10p regulate the life and death of cancer cells. NAT-activity is probably the major mechanism by which hNaa10p carry out its functions. The NAT-activity of hNaa10p is performed in concert with hNatA subunits as hNaa10p transfer an acetyl group from Ac-CoA to the a-amino group of a polypeptide N-terminus as it exits the ribosome.
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Nt-acetylation, or at least hNaa15p-dependence, was shown to be important for cell proliferation and cell survival, 46 ,47 DNA damage induced apoptosis 54 and autophagy. 54 The KAT activity of hNaa10p is probably a post-translational event where hNaa10p catalyze the transfer of an acetyl group from Ac-CoA to the e-lysine groups on internal sites of proteins. This activity is important for cell proliferation 48 and has been shown to reduce cell motility. 56 hNaa10p has also demonstrated an AT-independent activity where it enhance the activity of its binding partners 39 or block their ability to interact with other proteins. 55 This has been shown to be important for cell proliferation and reduction of cell motility.
Protein N-terminal acetyltransferases in cancer TV Kalvik and T Arnesen of cells while causing an accumulation of cells in the G 2 /M phase of the cell cycle, 83 indicating that hNatB is required for cell-cycle progression. This cell-cycle arrest was seen in conjunction with upregulation of p53 phosphorylated at Ser 15 and upregulation of p21. 83 In agreement with these findings, Starheim et al. 28 also reported an upregulation of p21 after knockdown of NAA20, whereas p21 was downregulated in cells depleted of the auxiliary subunit hNaa25p. This study also reported that depletion of hNaa25p caused cell death whereas depletion of hNaa20p mainly resulted in growth arrest. NatB subunits were shown to be overexpressed in murine and human hepatocellular carcinoma when compared with adjacent tissues, at least when investigating a limited number of samples. 83 Knockdown studies of the hNatC complex demonstrated that hNatC is required for proliferation and survival of cancer cell lines and could as such be involved in tumorigenesis and tumor growth. 15 Specifically, knockdown of the hNatC subunits lead to reduced cell proliferation and p53-dependent caspase-mediated cell death with upregulation of various p53 death-effector genes such as NOXA and KILLER. Unlike the Ser 15 phosphorylation of p53 that is seen with knockdown of hNatA and hNatB, p53 is instead phosphorylated at Ser 37 in hNatC knockdown cells. 15 This indicates that the p53-dependent cell death seen in hNatC knockdown cells is activated by a different pathway than in hNatA knockdown cells.
The Nt-acetyltransferase hNaa40p (hNatD) was recently characterized in humans, and was found to catalyze the Nt-acetylation of histones H2A and H4. 30 hNaa40p was previously found to be expressed at significantly reduced levels in hepatocellular carcinoma tissues, although presented here as the AT Patt1. 84 This might indicate that reduced levels of hNaa40p promote the development of hepatocellular carcinoma. Indeed knockdown experiments suggested that reduced levels of hNaa40p protects liver cancer cell lines from drug induced apoptosis.
hNaa50p is a catalytic subunit physically associated with hNatA, but is also defined as hNatE because of its intrinsic NAT-activity targeting specific substrate sequences. 27, 32, 33 Knockdown studies of Naa50p (called San in this study) in HeLa cells as well as in fruit fly have shown that the AT activity of Naa50p is essential for normal sister chromatid cohesion and chromosome condensation. 85 --87 In HeLa cells, hNaa50p depletion lead to M-phase cellcycle arrest, 85 indicating that hNaa50p is important for cell-cycle progression.
A similar phenotype with abnormal chromosome segregation was also observed in Naa60p (NatF) depleted Drosophila Dmel2 cells. Although Naa60p depleted Drosophila Dmel2 cells did not exhibit M-phase cell-cycle arrest as was observed for Naa50p depletion, they did show chromosome segregation defects such as lagging chromosomes and chromosomal bridges during anaphase. 2 This could indicate a role for Naa60p in mitosis, but also in tumorigenesis. The type of abnormal chromosome segregation observed in Naa60p depleted cells can lead to chromosomal instability. This condition can give rise to anueploid cells (abnormal number of chromosomes), a common feature of cancer cells. 88 
CONCLUSIONS AND FUTURE PERSPECTIVES
Further studies are needed to understand the function of NATs, how they are regulated, and through which mechanisms the oncogenic and tumor suppressor properties are mediated. A major step forward in the understanding of NATs in cancer cells would be to identify and verify the direct downstream NAT-substrates that could in greater detail explain the phenotypes observed when manipulating these enzymes. The majority of the studies outlined above indicate that hNaa10p or the hNatA complex is crucial to maintain cell proliferation and ensure cell survival of cancer cells. However, the huge number of Nt-acetylation targets of hNaa10p, perhaps up to 40% of the human proteome, 1 as well as its multifunctional role as a KAT and AT-independent regulator, make it likely that numerous pathways are simultaneously affected by increased or decreased hNaa10p levels. Thus, a multitude of variables downstream of hNaa10p will determine the end-point phenotype of a cancer cell. The known mechanisms by which hNaa10p may function as a tumor suppressor or oncoprotein are summarized in Figure 3 . Also, it is important to investigate the phenotypes in the light of the other subunits of the hNatA complex, namely hNaa15p, hNaa50p and HYPK. Although cotranslational Nt-acetylation by hNaa10p in most cases is likely to require one or more hNatA partners, the role as a KAT and an AT-independent regulator may not require these partners, but rather others.
Another important challenge is the identification of upstream regulators of NATs, in particular hNaa10p. In large solid tumors, hypoxia activates HIF-1a, which may bind hNaa10p and thereby disrupt the hNaa10p-b-catenin complex and thus disturb the activation of b-catenin that otherwise would positively regulate cell proliferation. 71 Unanswered questions remain: how does the binding of HIF-1a to hNaa10p affect the other known interaction partners of hNaa10p, how are the different functions of hNaa10p (NAT/KAT/AT-independent) affected and is the variety of observed phenotypes altered? hNaa10p-mediated autoacetylation is an essential step for its KAT-activity and thereby its ability to Protein N-terminal acetyltransferases in cancer TV Kalvik and T Arnesen acetylate and activate b-catenin. 49 This means that lysine deacetylases (KDACs) may regulate the KAT-activity of hNaa10p in cancer cells and thus affect its impact on cell proliferation. A question yet to be answered is: do the autoacetylation of hNaa10p, and the potential KDAC deacetylation, regulate other functions and effects of hNaa10p?
Ac-CoA recently emerged as a novel regulator of NAT-activity. It was revealed that the level of Ac-CoA regulates the level of Nt-acetylation of certain NatA and NatB substrates. 59 This means that the metabolic state of the cell may directly influence the catalytic activity of the NATs. Global Nt-acetylation proteomics profiling for a variety of metabolic states could address the generality of this regulation.
Specific NAT-inhibitors have not yet been developed and presented. Testing such inhibitors against various types of cancer at different stages might further shed light on the role of NATs in cancer under different circumstances. NAT-inhibitors may also prove to be effective in targeting certain types of cancer.
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The authors declare no conflict of interest. Figure 3 . Overview of the mechanisms and roles of hNaa10p in cancer cells. The NAT-activity of hNaa10p is carried out in concert with hNaa15p and possibly HYPK and hNaa50p and together they constitute the hNatA complex. The hNatA complex acetylates specific polypeptide N-termini as they emerge from the ribosome. 20 --22 Upon knockdown of hNatA subunits, growth arrest and induction of p53-dependent apoptosis were observed. 44, 46, 47 Taken together this suggest that hNatA has a signifcant role in cell proliferation and cell survival, although it is not entirely known by which pathways these phenotypes are mediated, as indicated by the dashed lines. Nt-acetylation has also been shown to promote DNA damage-induced apoptosis, possibly by modulating caspase activity, 58, 59 although the pathway is not entirely clear, as indicated by the dashed line. Nt-acetylation has been demonstrated to increase the stability and abundance of TSC2, which inhibits mammalian target of rapamycin (mTOR) activity. Reduced mTOR activity ultimately leads to increased autophagy, which may reduce cell proliferation. 54 Cell proliferation is also increased by the direct or indirect Nt-acetylation activation of AP-1 proteins (c-Jun and c-Fos) via the ERK1/2 pathway that in complex with bcatenin induce transcription of cyclin D1 and thereby cell proliferation. 49 The induction of cyclin D1 transcription is synenergetically complemented by direct or indirect KAT-activity of hNaa10p. The acetylation of e-lysine groups on b-catenin positively regulates cyclin D1 transcription. 48 Under hypoxic conditions, HIF-1a binds hNaa10p in a competitive manner and prevents the acetylation of b-catenin. 71--73 hNaa10p seems to be further linked to cell proliferation through direct interaction with DNMT1 in an AT-independent manner. This interaction enhances the silencing of the promoter of the tumor suppressor E-cadherin by methylation. 39 Finally, hNaa10p can reduce the cell motility of cancer cells by influencing two different pathways. In the first pathway it was proposed that hNaa10p binds competitively to PIX proteins in an AT-independent manner and thus prevents the activation of the cell migration machinery. 55 In the other pathway, hNaa10p directly bind and either directly or indirectly facilitate the acetylation of e-lysine groups on myosin light chain kinase (MLCK). Acetylated MLCK is unable to phosphorylate and activate mysosin light chain and thereby the cell contractile and migration machinery. 56 Protein N-terminal acetyltransferases in cancer TV Kalvik and T Arnesen
